De-escalating the BEACOPPescalated* regimen through a PET-driven strategy may reduce the risk of acute premature ovarian insufficiency (POI) in women with newly diagnosed advanced Hodgkin lymphoma (HL), subanalysis results of the phase III AHL2011 trial have shown.
Among patients with cancer who develop COVID-19, progressive disease and a higher ECOG* performance status (PS) are tied to an increased risk of mortality, according to early results ascertained from the COVID-19 and Cancer Consortium (CCC19) registry.
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
Female cancer survivors who undergo fertility preservation before cancer treatment often use their stored gametes/embryos. This highlights the effectiveness of pre-cancer fertility preservation, according to a study presented at ESHRE 2020.
The Malaysian Ministry of Health (MOH) via Clinical Research Malaysia (CRM) has announced its sponsorship of a medical oncologist for a fellowship in Phase 1 clinical research at an internationally renowned Canadian cancer centre.
The Val6Met polymorphism (rs6265) in the brain-derived neurotrophic factor (BDNF) appears to be protective against cancer-related cognitive impairment (CRCI) after chemotherapy, according to a recent Singapore study.
Researchers at the Technical University of Munich (TUM) and the German Research Center for Environmental Health (GRCEH) have shown arsenic trioxide, an approved treatment for acute promyelocytic leukaemia, may inhibit adenovirus infection.
An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.
Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.
At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.